Document Detail

Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy.
MedLine Citation:
PMID:  15920347     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: In chronic hepatitis C, early viral load decline after interferon administration is dose dependent and reflects the intrinsic viral susceptibility to the antiviral action of interferon. We examined whether the augmented suppression of susceptible viral loads by high-dose induction interferon could possibly discriminate responsive patients from non-responsive patients at an early stage of treatment.
METHODS: Fifty-nine chronic hepatitis C patients were randomly allocated to receive one of two treatment regimens; 3 MU interferon three times weekly plus ribavirin 1,000 mg/day for 24 weeks in the CR group (n = 30), and the same regimen as in the CR group except 10 MU interferon daily for the first week in the HR group (n = 29). Changes in viral loads during the first week of treatment were analyzed in terms of sustained virological response (SVR).
RESULTS: The positive predictive values of undetectable (<100 IU/ml) or low serum HCV RNA (<2,000 IU/ml) after 1 week of treatment for SVR were 100% in both treatment groups, whereas the negative predictive values of the low viral titer were 91% in the HR group and 70% in the CR group.
CONCLUSION: One-week virological response to high-dose induction interferon/ribavirin combination therapy is more predictive of SVR than conventional combination therapy in chronic hepatitis C.
Tae Hun Kim; Kyung A Kim; Young Seok Lim; Geum-Youn Gwak; Jung-Hwan Yoon; Gyeong Hoon Kang; Hyo-Suk Lee
Related Documents :
18215977 - Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve hiv...
571847 - Immunologic shin titration in leprosy patients and contacts.
2843137 - Failure of intraventricular gammaglobulin and alpha interferon for persistent encephali...
16082057 - Metabolic complications of antiretroviral therapy.
21389797 - Short-term and long-term vital outcomes of cirrhotic patients admitted to an intensive ...
24278647 - Minimum 3-year outcomes in patients with lumbar spinal stenosis after bilateral microde...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Intervirology     Volume:  48     ISSN:  0300-5526     ISO Abbreviation:  Intervirology     Publication Date:  2005  
Date Detail:
Created Date:  2005-05-27     Completed Date:  2005-07-07     Revised Date:  2011-03-09    
Medline Journal Info:
Nlm Unique ID:  0364265     Medline TA:  Intervirology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  230-8     Citation Subset:  IM    
Copyright Information:
Copyright (c) 2005 S. Karger AG, Basel.
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, 28 Yungun-dong Chongno-gu, Seoul 110-744, Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / administration & dosage,  therapeutic use*
Drug Administration Schedule
Drug Therapy, Combination
Hepacivirus / drug effects*,  physiology
Hepatitis C, Chronic / drug therapy*,  virology
Interferon Alfa-2a / administration & dosage,  therapeutic use*
Middle Aged
Predictive Value of Tests
RNA, Viral / blood
Ribavirin / administration & dosage,  therapeutic use*
Treatment Outcome
Viral Load*
Reg. No./Substance:
0/Antiviral Agents; 0/RNA, Viral; 36791-04-5/Ribavirin; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Evaluation of serum concentrations of human hepatocyte growth factor during interferon therapy for c...
Next Document:  Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in ...